Teva Pharmaceuticals last week announced it has obtained the FDA approval for Ajovy (Fremanezumab) for migraine prevention. The news boosted its shares. Indeed, many analysts expect the drug to generate annual sales up to $1bn (2021). Teva’s shares rose over 7% in pre-market trading today, after IBI Investments’ analysts had improved their expectations and Steven Tepper had published new estimates about Ajovy’s potential, that could generate up to $1.6-2.4bn pa, the Wall Street analyst said. Teva’s shares have risen 19.5% YTD.